general competitor has Lanham Act standing even if it doesn’t compete in alleged false advertiser’s subcategory

Colorado Biolabs, Inc. v. Three Arrows Nutra, LLC, No.
3:25-CV-0601-D, 2025 WL 2524313 (N.D. Tex. Sept. 2, 2025)

CBL sued Three Arrows for breach of a settlement agreement and
related claims; Three Arrows counterclaimed along similar lines. The parties
sell iron supplements. CBL sells Proferrin, an which contains heme iron polypeptide
sourced from bovine blood. This, allegedly, has a much higher absorption rate
than non-heme iron, and is more desirable than plant-derived iron insofar as it
can be taken with or without food and does not require a simultaneous dose of
Vitamin C for absorption. Before the lawsuit, Three Arrows’ products were
called IronRepair Heme Plus and IronRepair Simply Heme.

CBL noticed that Three Arrows’ products were colored brown,
not black like Proferrin, and got suspicious. “Internal testing of Three
Arrows’ products revealed that IronRepair Heme Plus contained only 3-7% of the
amount of iron represented on its label and that IronRepair Simply Heme
contained just 1-2% of the amount of iron reflected on its label. Further testing
by an outside laboratory revealed that Heme Iron was ‘not detectable’ in
IronRepair Simply Heme or IronRepair Heme Plus.” A lawsuit followed, which was
settled by Three Arrows, among other things, rebranding its IronRepair products
to eliminate all representations that the products constitute or contain Heme
Iron.

Afterwards, various members of the Iron Protocol Facebook
Group, an online community focused on iron deficiency, posted questions and
comments about the omission of the word “heme” from Three Arrows’ new labeling.
Three Arrows’ owner responded: “Nothing fishy going on. Heme iron is animal
derived. Iron Repair is made from bovine spleen only.” Asked for further
clarification, she responded that “[t]he batches currently in production will
list Iron 20 mg [a]s non-GMO grass fed & finished bovine spleen.” In
response to a question whether Three Arrows’ products are “all heme,” she
posted that “the iron is 100% derived from bovine spleen (animal sourced).” (Originally
she said “yes, the iron is 100% derived from bovine spleen (animal sourced),”
but after CBL notified Three Arrows that it was in breach of the Settlement
Agreement, she deleted the word “yes” from her post.)

CBL alleged that, through March 2025, Three Arrows tried to
“dupe” its customers into believing that the IronRepair products contain heme iron
by “simultaneously espousing the myriad benefits of Heme Iron over Non-Heme
Iron, making clear that Heme Iron comes from animal sources, and stating that
the IronRepair products are made with bovine spleen.” Its Amazon storefront also
allegedly marketed its IronRepair products as containing heme iron by using old
product labels and descriptions and Q&A responses that specifically include
the word “heme.”

In addition, Three Arrows Brand Ambassador Hartigan (who’s
paid a commission when customers buy using her discount code) manages and
administers the Iron Protocol Facebook Group. CBL alleged that, in response to
questions, Hartigan falsely communicated that the IronRepair products contain
Heme Iron and posted disparaging statements regarding CBL, Proferrin, and the first
lawsuit. Three Arrows allegedly didn’t correct these statements made on its behalf.

The settlement agreement didn’t bar claims based on conduct
post-dating the agreement.

Common-law business disparagement under Texas law requires
that “(1) the defendant published false and disparaging information about it,
(2) with malice, (3) without privilege, (4) that resulted in special damages to
the plaintiff.” “[P]roof of special damages is a ‘fundamental element of the
tort.’ ” CBL failed to allege special damages, which require “direct pecuniary
loss that has been realized or liquidated, such as specific lost sales, loss of
trade, or loss of other dealings.”

CBL alleged that, in the Facebook group, Hartigan posted
allegations that CBL only sued because it was “mad that they took a chunk of
their market share and wanted to bleed them dry in legal battles. Easier for [Three
Arrows] to settle on removing the word heme than going out of business due to
legal fees” and similar statements. One group member then posted, “boo
proferrin! I [heart] three arrows. I think this group and three arrows saved my
life.” But that statement didn’t indicate that the lawsuit, or Hartigan’s
comments, caused a lost sale as to that poster.

Lanham Act false advertising: were the statements disseminated
broadly enough to constitute actionable commercial advertising or promotion?
Three Arrows argued that the Facebook group wasn’t a commercial forum for
advertisements, but instead a private online community, and isolated posts
responding to others “are merely isolated comments unrelated to any commercial
advertising campaign.” It also argued that “[m]erely posting information on a
company’s own website, without more, is insufficient to establish broad
dissemination to the relevant consumer base” under the Lanham Act and that
“[t]he mere availability of product descriptions or comments on an Amazon
page—without allegations regarding paid promotions, sponsored product
placements, extensive advertising campaigns, or targeted consumer outreach—is
insufficient to constitute actionable advertising or promotion.”

That argument goes about as well as you’d imagine. The only thing
I’d even spend time on is the Facebook group. CBL alleged that it “has
approximately 166,300 members,” and that “[b]ecause of its focus and
membership, [it] is an important part of the iron supplement market and a
valuable source of potential iron supplement customers.” Good enough for a
motion to dismiss! Likewise, own-website and Amazon pages were “available to
the consuming public at all times.”

In its advertising-related counterclaims, Three Arrows
alleged that CBL implied in a post on the Reddit subreddit for persons with
anemia that Three Arrows admitted liability in the first lawsuit;
misrepresented on its own website that it is the only company that
manufacturers heme iron in the United States when at least one other competitor
also does so; and misrepresented to its customers the amount of heme iron that
its products contain (10.5 mg/capsule versus less than 10 mg).

CBL challenged standing, because Three Arrows isn’t a
domestic heme iron manufacturer and can’t make claims about its own products
having heme iron. Three Arrows argued that, as a competitor whose products are
made in the US, it was within the class of commercial actors with standing. The
court agreed. Three Arrows adequately alleged competitive injury within the
entire iron supplement market, not just the market for products containing heme
iron. (And of course disparagement gives standing to the disparaged
competitor.) Three Arrows’ alleged injuries—the loss of customers, confusion
and deception in the supplement industry, and the deprivation “of business and
good will”—were injuries to precisely the sorts of commercial interests the Lanham
Act protects.

from Blogger http://tushnet.blogspot.com/2025/09/general-competitor-has-lanham-act.html

Posted in Uncategorized | Tagged , | Leave a comment

3d Circuit affirmance shows that false advertising damages remain hard to prove

CareDX, Inc. v. Natera, Inc., 2025 WL 2480117, No. 23-2427,
No. 23-2428 (3d Cir. Aug. 28, 2025)

The court of appeals affirms the district court in this
Lanham Act/coordinate Delaware state law case based on allegedly false claims
Natera made about its organ transplant rejection detection product. A jury
found for CareDx and awarded it damages, which were vacated by the district
court.

The parties make and sell competing tests that use DNA to
detect whether a patient’s body has rejected a transplanted kidney: AlloSure (CareDx)
and Prospera (Natera). Natera’s advertisements pointed to results from two
studies—a Natera study on Prospera and a CareDx study on AlloSure—to
demonstrate Prospera’s superiority. Each study focused on accuracy: sensitivity
(false negatives, which are especially dangerous as untreated rejection
endangers patients) and specificity (false positives) as well as AUC (a composite
measure of the two) and negative predictive value (measuring the percentage of
correct negative results; higher NPV means fewer false negatives). The studies
varied in their designs and methods.

The jury heard testimony that the CareDx study was
multi-site, which meant that it could be generalized to the universal standard
of care, while the Natera study was single-site, and thus “considerably less
generalizable.” Likewise, the CareDx study used a prospective methodology,
which created a lower risk of selection bias because patients were first
selected and then biopsied and tested to see how AlloSure performed. But it
also sometimes generated ambiguous results, “based on the reality that certain
patients demonstrate partial rejection.” By contrast, the Natera study selected
from already-existing patient samples that had been tested for organ rejection
and were either “clearly not rejection [or] clearly rejection.” Also, the
cohorts were different, which matters because the prevalence of the underlying
condition—here, rejection—affects the sensitivity, specificity, and related
results, precluding an apples-to-apples comparison.

Thus, witnesses from both sides testified that the studies
couldn’t be directly compared—in contradiction to Natera’s advertising. The
jury found 9 of 10 challenged claims literally false, found willfulness, and
awarded $21.2 million in actual damages “attributable to Natera’s false
advertising and/or unfair competition,” and $23.7 million in punitive damages
“for Natera’s unfair competition.” The district court upheld the literal
falsity finding but found insufficient evidence to establish the actual deception
and reliance elements necessary for CareDx to recover damages under the Lanham
Act, and in turn, establish the causation and harm elements necessary to
recover damages under state law; prove wrongful interference with any business
relationship, thereby precluding liability on CareDx’s unfair competition
claim; and support a punitive damages award. Thus, the only remedy CareDx
secured was an injunction. (Wonder what would have happened if CareDx had
sought disgorgement.)

A plaintiff challenging establishment claims as literally
false “satisfies its burden by showing that the tests did not establish the
proposition for which they were cited.” There was sufficient evidence of that
here.

For example, Natera represented that Prospera is “[m]ore
sensitive and specific than current assessment tools across all types of
rejection.” Based on evidence that “current assessment tool[s]” referred to
AlloSure, a jury could reasonably find this was unambiguous and literally
false, because Prospera’s specificity rate was lower than AlloSure’s in both
studies, and the studies did not establish Prospera’s superiority given the
evidence that the studies were not comparable. Similarly, claims of “better performance”
“necessarily implie[d] that the studies are comparable and may be used to
establish Prospera’s superiority.”

Natera argued that its claims couldn’t be literally false
because they accurately reported the results of two studies. “However, by
placing the studies’ results side-by-side, alongside claims that Prospera is
superior to AlloSure, Natera necessarily implies that the results of the two
studies are comparable and establish Prospera’s superiority. A claim of
superiority based on comparison of incomparable metrics can be literally false.”
So too with “Unparalleled precision,” which was not ambiguous in the context of
a slide claiming superior sensitivity and NPV.

Likewise, a slide headed “[h]ighly sensitive across a range
of rejection types and patients,” and a subheading stating, “[v]ariety of
ethnic and racial demographics,” as well as “[a]ges,” including “[b]elow 18
years of age (n=49)” was also unambiguous. In context, “highly sensitive across
a range of … patients” above a subheading for various demographic groups,
including an age group of under 18-year-olds, unambiguously conveys that it is
highly sensitive for patients in that age group. Proximity mattered, and the
study didn’t establish Prospera’s sensitivity for patients under 18 (since the
ones in the study didn’t have any rejections).

For damages, a plaintiff must prove both falsity and actual
deception. Although a plaintiff need not “prov[e] detailed individualization of
loss of sales,” “there must be a showing of some customer reliance” on the
false claim. CareDx’s evidence of consumer confusion, Natera’s success, and
Natera’s willfulness didn’t suffice. (Once again I am pointing out that in a
trademark case, courts would draw the opposite conclusions.)

The testimony of two CareDx employees about confusion was vague
and conclusory, and failed to link the advertisements to any consumer
purchasing decisions. For example, the testimony that the ads “caused a lot of
confusion … with our customers,” and that although there was not “significant
patient impact initially,” later “there was more and more confusion, and then
… [more] usage of Prospera” lacked sufficient explanation. “These
generalities do not satisfy CareDx’s burden of introducing evidence sufficient
for a rational jury to find that consumers actually relied on or were deceived
by Natera’s false claims in deciding to purchase Prospera instead of AlloSure.”

What about the success of the ad campaign? The evidence
showed that (1) the comparative claims were a focus of Natera’s advertising
campaign; (2) a “small factor” in Natera’s increase of sales was that the
claims “pique[d] doctors’ interest[s]” in looking to the literature, and (3)
Natera’s sales team was successful in converting “at least one AlloSure user[
]” to Prospera. But that doesn’t show that consumers were actually confused.
Neither did Natera’s willfulness (apparently, internal emails showing that its
data folks raised concerns about the claims).

If you can infer bad intent from copying in trademark cases,
and likely confusion from intent, why not here? Damage is explicitly an element
in false advertising, and it should be but isn’t in trademark infringement, but
that difference doesn’t itself require prohibiting an inference of damage from
circumstantial evidence like the centrality of the false claim to an ad
campaign.

The court also rejected consideration of CareDx’s corrective
advertising costs, because although CareDx understandably worried about the
false claims, it still didn’t show lost sales. [If the corrective advertising
worked, how could it?]

from Blogger http://tushnet.blogspot.com/2025/09/3d-circuit-affirmance-shows-that-false.html

Posted in Uncategorized | Tagged , | Leave a comment

keyword ad claim fails out of the gate, but bad (c) claim not yet challenged

Regalo Int’l LLC v. Aborder Prods. Inc, 2025 WL 2483167, No.
3:24-CV-03270-E (N.D. Tex. Aug. 28, 2025)

Eric
Goldman on the keyword ad aspects
of this case about pet and baby gates.
Regalo alleged that Aborder sold “knock-offs of Plaintiffs’ patented safety
gates” that are “marketed the same [as Regalo’s gates] by misusing Plaintiffs’
copyrighted photographs and federally registered trademarks and otherwise
engaging unlawful, unfair competition.” This opinion doesn’t address the
copyright infringement claims, though they seem like obvious, fee-shift-worthy
junk to me. Crucially, despite referring to “trade dress,” there is no trade
dress infringement count, nor does the complaint allege secondary meaning for
the design of the gates.

When I read “copyright infringement,” I thought this would
be bog-standard photo copying. But no, Regalo thinks it owns the idea of a
picture showing a gate in a place you’d naturally put a gate, plus grateful
female homeowner.

Regalo’s “trade dress” (sic) in red boxes

Regalo photo

Regalo photo 2

Aborder gate with curved edges

Allegedly infringing Aborder photo 1

allegedly infringing Aborder photo 2

TM: Regalo tried to argue initial interest confusion based on defendants’ purchase of Regalos’ marks as ads in the Amazon eocosystem, but even in the Fifth Circuit, keyword advertising alone isn’t enough for IIC. There needs to be something else, such as a “click to call” ad leading to an extended conversation with a potential client—that is, something that approaches traditional bait and switch, with plausibly high sunk costs for the consumer.

The “something else” alleged here was (1) the visual similarity of the parties’ gates and (2) photos that “create product presentations that are confusingly similar to [Regalo’s] product listings.” The first is an unalleged product design trade dress claim, and the second is an unalleged packaging-type trade dress claim. Neither sufficed. The court found the allegations of confusing similarity conclusory. There were no allegations that the keyword ads were unlabeled (no screenshots were in or exhibits to the complaint) or that clicks resolved to deceptively generic purchase pages. In fact, Regalo alleged that clicks went to defendant’s product pages (labeled as such). General allegations that “many times” the sponsored ads “do not immediately make clear who the seller is” were insufficient to cross the line into plausibility.

The same vagueness doomed false advertising claims as to allegedly inauthentic customer reviews and systematic removal of negative reviews: “information and belief” wasn’t enough to call the reviews inauthentic or cherry-picked. Nor were the allegations that “a majority of [one defendant’s] reviews are rated with a scale of 1-5 without any comments, and nearly all of them positive” and that “over twenty of those reference Regalo and virtually all of them disparage or denigrate Regalo.” [But at least nobody disputed that fake reviews and review manipulation can be false advertising!]

The patent claims were plausible enough to need a claim construction hearing.

from Blogger http://tushnet.blogspot.com/2025/09/keyword-ad-claim-fails-out-of-gate-but.html

Posted in Uncategorized | Tagged , , | Leave a comment

9th Circuit finds laches in false advertising case

World Nutrition Inc. v. Advanced Supplementary Tech. Corp., 2025
WL 2427613, No. 24-4976 (9th Cir. Aug. 22, 2025)

Over a partial dissent, the court of appeals reverses the
district court’s refusal of a laches defense in this false advertising case,
giving no weight to the public’s interest in avoiding deception. (Lower
court ruling discussed here
.)

The parties both advertised some of their respective enzyme
products as having, to varying degrees, enteric coating. After a bench trial,
the district court (1) rejected defendant AST’s laches defense; (2) ruled in
favor of World Nutrition on its claim and in favor of AST on two of its three
counterclaims; and (3) entered a monetary judgment in World Nutrition’s favor
because it determined that AST made more than World Nutrition did from the
deception.

The district court abused its discretion by rejecting AST’s
laches defense. Laches requires unreasonable delay plus prejudice. Reasonability
considers both the time allotted by the “analogous” state statute of
limitations and any “legitimate excuse” for delay. But the district court
considered only prejudice, which can’t be viewed in isolation from the delay. When
a court determines that “the most analogous state statute of limitations
expired before suit was filed,” a “strong presumption in favor of laches”
attaches, and ourts must “bear[ ] in mind th[at] presumption” when evaluating
prejudice.

World Nutrition knew—or at least should have known—about its
false-advertising claim by 2011, and the analogous statute of limitations is Arizona’s
three-year period for fraud. That expired in 2014, five years before World
Nutrition sued. Thus, the district court abused its discretion in failing to
evaluate prejudice without a presumption thereof.

Given that presumption, AST showed laches. World Nutrition
offered no legitimate excuse for its delay. And the district court, addressing
a different issue, relied on its determination that “AST centered its
advertising—and spent substantial funds—on the claim that its products were
more effective because of the enteric coating.” That finding, which was not
clearly erroneous, showed prejudice, which exists when a defendant invests
resources—whether through advertising or otherwise—to “build a valuable
business around [the specific business asset or practice being challenged]
during the time that the plaintiff delayed.”

The court of appeals affirmed the district court’s finding  that AST failed to meet its burden to prove
the literal falsity of World Nutrition’s advertising of its liquid products as
“100%” effective. Still, a good result for AST.

Judge Ryan Nelson dissented in part, because he would have
sent it back to the district court to reassess laches in the first instance.

from Blogger http://tushnet.blogspot.com/2025/08/9th-circuit-finds-laches-in-false.html

Posted in Uncategorized | Tagged , | Leave a comment

graphic designer’s photos and hashtag using former client’s name didn’t infringe TM

Hilber v. Malley’s Candies, Inc., 2025
WL 2402329, No. 1:22-CV-02305 (N.D. Ohio Aug. 19, 2025)

Advertising is often
created by independent contractors, which has copyright risks when things go
sour. Here, the court denies summary judgment on the defendant’s implied
license defense, and also rejects its overreaching trademark counterclaims
about its designer’s use of images on the designer’s social media accounts.

Malley’s is a chain of candy and confectionary stores in
Northeastern Ohio, and Hilber is an independent consulting graphic design
artist. Hilber charged Malley’s an hourly rate of $50 per hour to perform the
graphic design work for advertising campaigns, with no written agreement. Malley’s
purchased a camera for her to use to create photography and artwork for
advertising campaigns. Between 2018 and 2021, she invoiced Malley’s for more
than $230,000. She provided print-ready files, not the native files, and was
the only one to make modifications. The relationship broke down and produced
this lawsuit.

Malley’s previous graphic designer independent contractors
didn’t think they owned their work for Malley’s. (They were wrong, but that
expectation is highly relevant to the implied license.)

The court denied summary judgment on the implied license for
continued use/modification. Malley’s also counterclaimed against Hilber’s use
of photographs of Malley’s products on her Instagram and Facebook accounts and
on her website:

Instagram

Website

Facebook, I think

Hilber allegedly used these photographs of Malley’s artwork,
as well as the hashtags “#malleys” and “#graphicdesigner,” to advertise her
services as a graphic designer.

The court was unconvinced. Since we’re in the Sixth Circuit,
what might be considered nominative fair use elsewhere is just mushed into the
general infringement/ “use in a trademark way” inquiry. Malley’s was unable to
identify anyone who was actually confused or any profit Hilber made from the uses.

Malley’s appealed to Sixth Circuit caselaw holding that continued
unauthorized use of a trademark is enough to establish likelihood of confusion.
But those were terminated franchisee cases, where the defendants were providing
the same service as the franchisor. “Hilber is not holding herself out as
providing the same products as Malley’s. She is sharing Malley’s social media
posts and displaying images of work she created.” Given the unrelatedness of the
goods or services, confusion was highly unlikely. [Courts default to source
confusion when they don’t like extended confusion theories, usually without
even explaining why they aren’t addressing sponsorship/affiliation confusion.] “[N]o
rational trier of fact could find that Hilber, by displaying Malley’s products
and logos on her social media or personal website, likely caused confusion
among consumers seeking to purchase Malley’s products.”

Hilber’s use of the hashtags “#malleys” and “#graphicdesign”
in Instagram posts was also ok:

 

In the cases Malley’s cites, the
defendants used hashtags to create a public impression their products or
services were endorsed by the trademark owner. In those case, the use of
hashtags was likely to cause confusion because the defendants were selling the
same products or services as the trademark owner and wanted to convey an
association to obtain business. The cases are distinguishable. Hilber is not
selling candy or chocolate. She is a graphic designer. She is not unfairly
competing with Malley’s for consumers looking to buy chocolate by using the
hashtag “#malleys.” Hilber has not received any

State dilution claims also failed, even though the trademark
was “identical.”  Without evidence of “personal
gain,” the court wasn’t even willing to accept that Hilber was “using” a junior
mark “in commerce,” nor was there evidence of dilution. [How could there be?] “And
Malley’s cannot distinguish Hilber’s posts from the thousands of other social
media users that post Malley’s marks.”

 

 

from Blogger http://tushnet.blogspot.com/2025/08/graphic-designers-photos-and-hashtag.html

Posted in Uncategorized | Tagged , , | Leave a comment

literal falsity wasn’t enough without evidence of lost sales or harm to goodwill

G. W. Aru, LLC v. W. R. Grace & Co.-Conn., No.
JKB-22-2636, 2025 WL 2402194 (D. Md. Aug. 19, 2025)

Previous
decision resolving some pretrial issues
; this opinion comes after a bench
trial, which resulted in a ruling for defendant Grace on both the patent and
false advertising claims:

GWA and Grace both sell to
refineries products called CO-to-CO2 combustion promoters. At a high level, GWA
claims that Grace copied GWA’s patented combustion-promoter technology while
embarking on an advertising campaign that falsely inflated the performance of
Grace’s products and denigrated GWA in the eyes of potential buyers.

At least for people in sophisticated industries, the
decision offers a roadmap for convincing a court that advertising claims are
not ultimately material, no matter how factual or central they seem at first.

Domestic buyers of combustion promoters are about 110 FCC
refineries in the United States, owned by about thirty companies. (Neither
Grace nor GWA is the biggest competitor in the field, if you’re wondering,
although it’s not a crowded market; Grace has between 20-30% of the market and
GWA has made at least some sales to about half of the relevant companies. In the
abstract, “if a sale does not go to Grace, it is at least as likely (indeed,
probably more likely) that it would instead go to [largest player] JM rather
than to GWA.”

Grace’s OCPP purported to offer the same or similar
performance as CPP, but at a lower cost. It published an article entitled “CO
promoter technology development” in Petroleum Technology Quarterly, a trade
magazine for the petroleum refining industry. This stated:

A customer performed a trial
comparing Grace’s Optimized CPP technology versus a competitor’s lower
palladium promoter. … On average, the usage rate for Optimized CPP decreased by
64%…. Even though there was a lower usage rate of Optimized CPP, the
afterburn was reduced by 11% [compared to the competitor].

The article also claimed the “additional benefit of lower
NOx emissions,” and that OCPP particles have a higher proportion of noble
metals “residing on the outer surface of the particle.” The PTQ Article was
based on a case study of a trial conducted at Valero-Wilmington, which compared
the performance of GWA’s GFP with Grace’s CPP and OCPP. The author stated in an
internal Grace email that he wanted to “work” the analysis “into a marketing
package, to support the roll out of Optimized CPP, and to protect/capture
business vs GWA.”

Did claims in emails to potential clients constitute
“commercial advertising or promotion”? Yes, they were sufficiently disseminated
given the size of the market. “Taken together, a large minority of FCC units
throughout the United States received the promotional materials.” Grace argued
that the relevant market was worldwide market, but “the law is clear that an
organized campaign targeting a significant subset of customers is sufficient.”
The statements were prepared with the expectation of being used for a marketing
campaign, and were so used.

Falsity: Grace ultimately didn’t contest that there were
errors in the data and their evaluation.  The comparative-performance claims were
literally false because they were not supported by the data on which Grace
relied. Some industry participants read PTQ regularly and consider it to be
well-known in the petroleum refining industry, while others never read PTQ or
have never even heard of it. “[I]n the absence of additional evidence specific
to a particular refinery, it is merely possible—not likely—that a buyer at that
refinery had read any portion of the Q2 PTQ issue (much less the specific
article at issue in this case) before purchasing OCPP.”

Grace also made a similar blog post, but “[t]he only witness
who testified to seeing the blog post before this lawsuit began was [plaintiff’s
principal] Mr. Aru himself.”

Grace also prepared “data sheets” containing much of the
same information, including comparative-performance claims, NOx claims, and
“outer surface” claims. These were often sent by email to refineries or shared
during meetings. They also often made more detailed claims about NOx emissions
(the “test-validated NOx claims”).

Although the article’s author put together a “marketing case
study,” he also contemporaneously received information from the data collector
that OCPP performed merely fifty-four percent better than the competition, not
sixty-four percent as Grace would later claim. Meanwhile, in internal Grace
communications, he repeatedly stated that OCPP’s performance as compared to GFP
was the same or merely slightly better, and stated that, in a trial at another
refinery, it actually performed worse. “In other words, at the very same time
that Grace was trumpeting a sixty-two or sixty-four percent improvement,
Grace’s internal communications show that the company knew the products
basically performed the same.”

The lower NOx emissions claims, however, had weak support;
because GWA had the burden of persuasion on falsity, it failed. The test-validated
NOx claims could be based on a ten-year-old study, because that study “included
data on at least one batch of combustion promoter that was materially identical
to modern-day OCPP.” GWA didn’t offer any reason to think that the underlying
science has changed. Even if Grace implied that its testing was recent and
conducted on actual commercial OCPP samples (as opposed to test samples that
were functionally equivalent), “misleading implications will generally not
support a finding of literal falsity.”

GWA’s real troubles were materiality and, relatedly, harm.
Although the comparative performance claims were likely to influence a
refinery’s decision whether to trial OCPP, they were unlikely to have much
influence on a refinery’s decision to purchase OCPP long term. And the
test-validated NOx claims (assuming falsity) were not likely to influence the
purchasing decision.

In the industry, advertising was just not very important:

Selling combustion promoters is not
like selling soft drinks. A splashy advertising campaign is simply not going to
move the needle very much for the target audience. The evidence at trial showed
that buyers in the combustion-promoter market are hard-nosed engineers and
corporate executives who are focused on their bottom line at their refineries.
They are inherently skeptical of any promotional claims—and they have the means
to independently verify such claims. They closely monitor, on an essentially continuous
basis, performance metrics at their facilities. Furthermore, they almost
universally insist on doing their own testing of any product before making a
long-term purchase.

Buyers in the petroleum refining
industry do not take advertisements at face value. Perhaps most strikingly, two
witnesses called by GWA expressly denied ever relying on something in a PTQ
publication when making a purchasing decision. …

Further, testimony indicated that
some customers might have found the comparative-performance claims implausible
on their face, or else too vague to be given any weight. Even if customers
thought the claims were accurate in the narrow sense of representing the
performance of that specific trial, they might still doubt whether the product
would perform as well in their own refinery. There is a high degree of
variability in FCC units, such that a product that works well in one unit might
not work nearly as well in another.

Ads do “play a limited, but important, role in getting the
seller’s foot in the door of a potential buyer.” Because of their continuous
monitoring, a refiner will “know pretty quick” after trialing a new product “whether
it’s working or not.” A trial does not guarantee a long-term sale, as multiple
instances in the record confirmed.

“Several of the issues highlighted in the Grace
advertisements—control of afterburn, control of CO emissions, control of NOx
emissions, and cost-effectiveness—are among the most important considerations
for combustion-promoter buyers.” Thus, the comparative-performance claims were,
at least in the abstract, likely to influence a refinery’s decision to trial
OCPP. “Although purchasers are inherently skeptical of promotional claims, they
do not ignore such claims either. Instead, they consider promotional claims as
part of the totality of information they would review in deciding whether to
try out a new product.”

Non-advertising factors such as risk, price, and vendor
relationships also affect buying decisions. Grace often charges more than competitors,
in part because it offers high-quality technical support and can often
troubleshoot within a twenty-four- to forty-eight-hour window, which is “among
the best” in the industry and which GWA couldn’t always match. Each day that an
FCC unit is offline could translate into “thousands or tens of thousands of
dollars” lost. Grace is also more protected against supply disruptions than
GWA, and, as a larger company, offers a full range of products, allowing it to
offer package deals and a single source solution. Combustion promoters are a
small percentage of refineries’ costs, on the order of five percent or less of
refineries’ spending on FCC products, so they may not be central to purchase
decision.

Ultimately, the comparative-performance claims were likely
to influence a trial, but not a long-term purchase. And the
“test-validated NOx claims” were also unlikely to influence the buying
decision—not even for a trial run.

In these circumstances, it didn’t matter that the statements
“relate to inherent qualities of combustion promoters” or “that Grace hoped
that its advertisements would influence consumers.” “Clearly Grace must have
expected some benefit from its advertisements; the Court would not lightly
conclude that Grace views its own advertisements as a waste of money.” But
there’s a differnece between finding that advertisements “lead to prospects” in
the relevant market and finding that the advertisements were “likely to
influence any purchasing decision.” Not all advertising is material as a matter
of law. Still, Grace’s intentions “are highly relevant insofar as they reflect
the outcomes that seasoned industry insiders expected from the advertisements.”

“[N]umerous courts have found an absence of materiality in
Lanham Act false-advertising cases when the target audience consisted of
sophisticated individuals who were unlikely to be swayed by promotional
materials.” But in the market here, a trial was a sale, “albeit a small one,”
and the statements here were material to a decision to run a trial—the only way
for a refinery to evaluate claims like this. The court also noted that, “although
the exact scale of the errors in the comparative-performance claims is unclear,
Grace’s own communications suggest that they were overstated by at least a
factor of two. This was no minor misstatement; instead, Grace’s
comparative-performance claims were simply wrong, perhaps extremely wrong.”
That’s relevant to materiality too.

Even though no witness admitted to being influenced by an
ad, “the Court infers from the evidence that the advertisements were likely to
influence purchasers’ decision to run a trial.” That’s enough for materiality,
which is distinct from injury. [It wasn’t always, historically.]

And GWA was unable to show injury on a refinery by refinery
basis. No witness testified that the challenged claims had any actual influence
on their decisions or caused them to think less of GWA or GWA’s products
(though they agreed that this was hypothetically possible), and GWA was able to
identify only a single lost sale (but it didn’t seek disgorgement for that
refinery, and the reason for the lost business wasn’t based on Grace’s ads but
on errors on GWA’s end). 

GWA argued that, because it sought disgorgement, it need not
prove “actual damages, only a likelihood of injury.” But likely injury is an
element of the underlying liability determination (as it isn’t for trademark
infringement). “[W]henever a plaintiff seeks to invoke the Lanham Act to remedy
a past violation, it must show that the violation proximately caused an actual
injury.” The requirement that a plaintiff seeking monetary relief for past harm
have suffered an actual injury

“is not a minor or technical
element of a Lanham Act claim; indeed, as the Supreme Court has explained, it
is the core requirement that a plaintiff ‘show economic or reputational injury
flowing directly from the deception wrought by the defendant’s advertising’
that assures Article III standing in Lanham Act cases.” Stemming as it does
from foundational jurisdictional principles, this requirement is not lessened
when the financial remedy sought is equitable (e.g., disgorgement of ill-gotten
profits) rather than legal (e.g., damages) in nature.

[Now do trademark!] A Lanham Act plaintiff seeking equitable
monetary relief need not prove the specific dollar amount of harm it suffered,
but still must satisfy the actual injury requirement. But what about cases that
say things like “[t]he Lanham Act permits recovery of profits because actual
damages are often difficult to prove. It ‘shifts the burden of proving economic
injury off the innocent party, and places the hardship of disproving economic
gain onto the infringer.’ ” Hard Candy, LLC v. Anastasia Beverly Hills, Inc.,
921 F.3d 1343, 1353 (11th Cir. 2019)? They must “be read in harmony with Lexmark’s
admonition that a Lanham Act plaintiff seeking monetary relief must plead and
prove actual injury proximately caused by the defendant’s conduct.” Such cases
mean only “that a plaintiff (1) need not prove the specific dollar amount of
losses it suffered and (2) need not prove economic harm at all, because
non-economic harms, such as a loss of goodwill, are sufficient.” [How are those
shown in trademark cases, again?]

The statute’s burden-shifting on disgorgement “means at most
that, if, but only if, a disgorgement-seeking plaintiff has persuaded the
factfinder that it suffered some injury proximately caused by the defendant’s
false advertising, then the burden shifts to the defendant to prove that
certain sales were not attributable to that false advertising.… In other words,
a plaintiff can unlock the doors to the Lanham Act’s favorable burden shift
only after it has first proved that it suffered an injury proximately caused by
the defendant’s violation.”

That was fatal. Even if Grace’s advertisements were “one
factor among many that may have contributed, in some attenuated sense, to GWA’s
not having made sales to the refineries at issue, … that alone is not enough to
satisfy the proximate-cause requirement.” The injury (if any) “might instead
have resulted from ‘any number of other reasons.’ ” Nor did GWA show any harm
to its goodwill.

from Blogger http://tushnet.blogspot.com/2025/08/literal-falsity-wasnt-enough-without.html

Posted in Uncategorized | Tagged , | Leave a comment

class certification partly granted in Tesla self-driving case

In Re Tesla Advanced Driver
Assistance Systems Litig., No. 22-cv-05240-RFL, 2025 WL 2391446 (N.D. Cal. Aug.
18, 2025)

While not adopting
all plaintiffs’ arguments, the court certifies a limited class to challenge Tesla’s
full self-driving claims. I’m going to omit a lot, but the claims are the
usual California statutory claims
plus fraud, negligent misrepresentation, and negligence.

Of note, because Tesla
doesn’t pay for traditional marketing/advertising, “it reaches consumers
directly through its website, as reinforced by its own YouTube, Instagram,
press conferences, sales events, marketing newsletters, and CEO Elon Musk’s
personal Twitter account.” There’s a bizarre redaction of historical fact about
the prices offered to the public: “Tesla has historically offered customers the
ability to purchase or subscribe to optional technology packages—ranging from
[redacted] to [redacted] in price—designed to enable autonomous vehicle
operation.”

Plaintiff allegedly
relied on two misrepresentations to pay an extra $8000: (1) that Tesla vehicles
are equipped with the hardware necessary for full self-driving capability, and
(2) that a Tesla vehicle would be able to drive itself across the country
within the following year. Musk touted the hardware for “full self-driving for
driver-less capability” in 2016, claiming it was “in every car we make.” These
statements also appeared on Tesla’s website, including on the Autopilot, Model
S, and Model X subpages, and other places.

Hardware updates
followed, and “Musk later stated on a 2024 earnings call that a hardware
upgrade may be necessary for customers who purchased FSD with prior hardware
configurations.”

In 2016, Musk also
claimed that “we will be able to demonstrate a [demonstration] drive of our
full autonomy all the way from LA to New York.” He tweeted words to this effect
three times. Embarrassing: “While Musk’s Twitter account has over 200 million
followers, the 2019 Tweet generated around 2,000 engagements, and the 2017
Tweet generated around 300 engagements.” Also in 2016, “Tesla began displaying
a video that showed a Tesla driving autonomously, which remains on the Tesla
site today” and was also on YouTube.

It’s undisputed
that Tesla has not yet provided cross-country capability, and Tesla has not even
applied for regulatory approval to deploy a Society of Automotive Engineers  Level 3 or higher vehicle in California, which
is a necessary step for approval of a full self-driving vehicle. Before this
ruling, the court compelled arbitration as to one group of plaintiffs and dismissed
all warranty claims but permitted fraud-based, negligence-based, and related
statutory claims based on the statements above.

The court thus
certified a class of California purchasers/lessees who opted out of the arbitration
agreement or who paid before the arbitration agreement came in and who bought
or leased while the key statements were being made.

The number of
people estimated to be in the class was redacted (again, why?) but numerosity
was satisfied.  Commonality and
predominance were also satisfied because the case turned on whether Tesla’s
statements were deceptive to a reasonable consumer. Tesla argued that there was
no showing of class-wide exposure where there was neither a product label nor a
traditional mass advertising campaign.

Plaintiff met his
burden of showing class-wide exposure on the hardware statement, but not the
cross-country statement. The hardware statement was (1) on the “Autopilot”
subpage of Tesla’s website from October 2016 until August 2024; (2) on various
other subpages of Tesla’s website, including the “Model X” and “Model S” pages,
at points throughout that period; (3) disseminated by Musk at a high-profile
conference in 2016; (4) stated in a Tesla blog post published in October 2016;
(5) stated in a Tesla quarterly earnings call in May 2017; and (6) sent via
newsletter to prospective and current Tesla vehicle owners in 2016. “While
these channels alone may not ordinarily be enough to establish class-wide
exposure for a traditional car manufacturer, Tesla’s distinctive advertising
strategy warrants a departure from the typical approach.”

Given Tesla’s
direct-to-consumer sales and lack of independent dealers, consumers are “highly
likely to visit the website when considering the purchase of an expensive
package such as EAP or FSD.” The undisputed evidence “indicates that the
Autopilot page is the principal source of detailed marketing information from
Tesla, and typically the only written source of such information, describing
the supported features and how they work. Additionally, consumers can order
those packages directly through the site.” Thus, “it is reasonable to infer
that almost all consumers spending thousands of dollars on the packages would
review Tesla’s description to make that decision.”

Further, “because
Tesla itself serves as the primary source of product information, it is
reasonable to infer that the few alternative sources available to
consumers—i.e., YouTube videos demonstrating self-driving capability,
word-of-mouth, news articles—reinforce Tesla’s core message that full-self
driving capability is on the horizon, even if they do not specifically contain
the Hardware Statement.” Plaintiff’s expert also supported this finding. However,
without the hardware statement on the Tesla site, “the remaining channels of
communication are insufficient to support an inference of class-wide exposure,”
which led the court to limit the class period to the time the statement was on
the site.

As with product labels,
“though some consumers may not read the packaging when opening an item, courts
have inferred class-wide exposure based on the ‘inherently high likelihood’
that consumers would have relied upon those representations when encountering
them in the course of purchasing the product.” Monthly Tesla website traffic
data did not show otherwise; Tesla contended that only a few thousand people
visited tesla.com/autopilot the related blog post:

But
this information has little bearing on the key issue of the proportion of FSD
purchasers who viewed those pages, as it is reasonable to assume that many
people visit the Tesla website for reasons other than to purchase FSD.
Moreover, the table does not include the number of monthly visits to the Model
X and Model S subpages, which also contained the Hardware Statement at certain
points throughout the relevant time period, and is missing large portions of
data (i.e., from January to November 2017 for tesla.com/autopilot). Indeed, the
view counts are consistent with a finding of class-wide exposure, as it appears
thousands of people on average—which does not include those using ad
blockers—viewed the Autopilot page and blog post each month throughout the
class period. Tesla has therefore failed to rebut Plaintiff’s showing of
class-wide exposure as to the Hardware Statement.

But the
cross-country statement was less well-disseminated (Musk only said it four
times and didn’t get much engagement when he did), so class-wide exposure was
not established.

Materiality is an
objective standard, and plaintiff showed it with testimony from a marketing
expert who explained that these statements were material “due to the objective
credibility of the speakers (i.e. Tesla itself and Musk, Tesla’s CEO and an
industry leader), existence of multiple channels conveying a consistent
message, centrality of statement to the product’s core qualities, and clear
nature of the promise.”

Tesla argued that its
disclosure on the Tesla website that FSD functionality was subject to
“validation and regulatory approval,” as well as other “manuals, contracts and
[ ] documents [that] made it crystal clear that the technology was for ‘driver
assistance’ and NOT to replace the driver” disproved materiality. But “a
consumer can simultaneously believe that his car has the hardware necessary to
enable full self-driving and that such functionality would only be released to
him after regulatory approval.” The “manuals, contracts and [ ] documents,” likewise
referred to a Tesla vehicle’s current capabilities, not the full self-driving
capability touted by Tesla and Musk as being possible using the existing
hardware. Nor did the testimony of a “handful” of customers perceiving the
Hardware Statement to be “mere puffery” undermine the common evidence
demonstrating materiality, because the standard is objective. However, this
conclusion only applied to the FSD package, not a lesser package.

Tesla also argued
that falsity wasn’t subject to common proof because it kept tweaking the
hardware. But Plaintiff’s expert reviewed the sensor and compute configurations
for Tesla vehicles throughout the class period and testified that, for example,
“[t]he [in]ability for the sensors to perform in bad weather” is a limitation
that would be common across the different hardware versions. “Moreover, that
Tesla has been unable to demonstrate a long-distance autonomous drive with any
of its vehicles or obtain the required certifications to do driverless testing
in California further supports the lack of full self-driving capability across
the class.”

Damages were also
subject to common proof because plaintiff’s theory was that the appropriate
measure of damages would simply require refunding class members the amounts
paid for their purchases or subscriptions to FSD.

Nor would statute
of limitations issues preclude class treatment; individual application of a
limitation period to a class member rarely does. Also, the delayed discovery
rule and equitable estoppel theories of tolling “turn primarily on the
objective inquiry of whether Tesla’s misrepresentations to the class stopped a
consumer from discovering the cause of action or pursuing a lawsuit.”

The court also
certified an injunctive class of members of the classes above “who have stated
that they would like to purchase or subscribe to FSD in the future but cannot
rely on the product’s future advertising or labelling.” Tesla argued that this
was subjective, but ascertainability is not a requirement for certifying a Rule
23(b)(2) class.  And the requested
injunctive relief was clear enough: “Plaintiff seeks to stop Tesla from
continuing to state that its vehicles have the hardware capable of full
self-driving until the vehicles are actually able to do so.

from Blogger http://tushnet.blogspot.com/2025/08/class-certification-partly-granted-in.html

Posted in Uncategorized | Tagged , | Leave a comment

Recommended reading: Jessica Litman, Authorship Nonsense

 Read it here.

Abstract:

Copyright law’s primary device for promoting progress is to bestow
rights on the authors of works. Rights vest automatically and last for a
very long time. Authors’ choices to retain, license, or transfer those
rights fuel opportunities to communicate the works to their audiences.
The copyright system’s mechanisms for determining who authored works
(and therefore automatically obtained copyright rights) should be both
accurate and reliable, since misidentifications will undermine the law’s
working as intended. 

This article examines authors’ creation
of works and copyright law’s handling of authorship disputes. Many works
result from creative collaboration. Although the copyright statute
incorporates mechanisms for allocating rights among multiple
contributors, judges appear to be uncomfortable with severally-authored
works. Accordingly, courts have adopted rules that minimize, reallocate,
or erase the creative contributions of inconvenient collaborators.
These well-settled rules are nonsense, neither well-reasoned nor
probative. They complicate and confuse our efforts to identify the
author and owner of copyright in a work, and exacerbate power
disparities in unbalanced creative ecosystems. 

from Blogger http://tushnet.blogspot.com/2025/08/recommended-reading-jessica-litman.html

Posted in Uncategorized | Tagged , | Leave a comment

court rejects Schedule A claims against sellers of compatible parts/accessories

Bestway Inflatables & Material Corp. v. Individuals,
Corporations, Limited Liability Companies, Partnerships, & Unincorporated
Associations Identified on Schedule A Hereto, 2025 WL 2380699, No. 24 C 11697
(N.D. Ill. Aug. 15, 2025)

When they tell you that Schedule A cases are against
counterfeiters, keep in mind that trademark owners are willing to call pretty
much anything “counterfeiting,” including ads for compatible parts. Here, the
court looks into the allegations—assisted by defendants who showed up—and concludes
that they’re implausible as to the fighting defendants (those who weren’t
dismissed due to settlement—which this result suggests may have been unnecessary).
What about the rest? The court allows them to show up on their own and repeat
the prevailing defendants’ arguments—which probably won’t do much to curtail
the practice absent some big fee shifts.

Defendants sell parts and accessories for above-ground pools
via internet storefronts on third-party platforms, including Amazon.com, where their
listings mention Bestway as a maker of equipment with which their products are
compatible. Each of defendants’ listings “states in some way that their
products are compatible with Bestway pools or meant for use in Bestway pools,”
e.g., one listing states that its cup holders are “[p]erfect for above ground
pools of brands such as Bestway, Intex, Funsicle, Summer Waves … Coleman, etc.,”
while another defendant’s listings state that its pool plunger valve is “for
Intex/Bestway/Coleman Pool[s]” and its pool pipe holder is “for Intex Bestway
Coleman Above Ground Pool,” and another says that its pool hose adapter is “for
Bestway for Coleman for Intex” and its joint hose connector is “for Intex
Bestway Coleman.”  

As a general matter, “it is not trademark infringement for a
manufacturer of parts to truthfully inform buyers that its parts will fit the
trademarked product of another manufacturer.” However, “the exact language of
the advertisement will be carefully scrutinized” to ensure that it is not
“confusing as to source, sponsorship, affiliation or approval.” Here, the
listings “plainly used the mark ‘Bestway’ not for any source-identification
function as to their own products, but only to indicate that their parts and
accessories are compatible with Bestway pools.” Each listing referred not only
to Bestway but also to at least one other manufacturer of above-ground pools,
such as Intex or Coleman.

Defendants pointed to an earlier Schedule A case, Roku Inc.
v. Individuals, Corps., LLCs, Partnerships, & Unincorporated Associations
Identified on Schedule A Hereto, No. 22-CV-0850, 2022 WL 1598208, at *4
(S.D.N.Y. May 20, 2022), which concluded that the holder of the “Roku”
trademark had not shown a likelihood of confusion based only on an Amazon
listing of a remote that was listed as “compatible” with Roku TVs, reasoning in
part that the fact that the remote had a “Roku channel” button did not
communicate sponsorship or a common origin with Roku-manufactured products when
there were also buttons for “Netflix, Hulu, [and] Disney+.” It was clear in
context that the defendant’s use of the term “Roku” in its listing referred to “legitimate
Roku products,” not to defendant’s own products. The same was true here. There
were no non-conclusory allegations of actual confusion or intent to palm off.
And, though “[a] superficial glance at the other likelihood of confusion
factors might seem to suggest that they favor Plaintiff, … any such assessment
would fail to account for context and common sense.” The mark was used “in its
simple textual form,” along with the marks of competing above-ground pool
manufacturers, “to inform consumers that their parts will fit the pools of
those manufacturers.” If “Bestway” had been in larger font than the rest of the
text or singled out in some other way, the result might have been different. [This
is nominative fair use without the label, deployed as implementation of Twiqbal.
If all we have to limit trademark rights is context, then it’s good for courts
to take context seriously. But the Seventh Circuit has a very distinct attitude towards common sense.] Here, the mention of other competitors signalled a
lack of source- or sponsorship-indicating use, suggesting that “Bestway” was
being used “not to indicate sponsorship but only to identify Plaintiff’s pools
as an example of one kind of pool that Plaintiff’s parts and accessories will
fit.” If these listings could infringe,

it is hard to see how anyone in
Defendants’ position could sell replacement parts without risking a trademark
infringement suit, short of offering an explicit disclaimer—i.e., “These parts
are not manufactured by Bestway, Intex, or Coleman.” Plaintiff has cited no
authority requiring such language in circumstances such as these, nor does the
Court see anything plausibly misleading or confusing in Defendant’s listings
that might require some such corrective disclosure.

The court didn’t reach “fair use” arguments as such because
confusion was implausible. Two other defendants filed motions for summary
judgment on similar grounds, but the parties hadn’t yet had an opportunity for
discovery; those defendants could now refile. (If the grounds were similar,
what more could discovery have revealed that would change the content of the
listings over which plaintiff brought suit?)

from Blogger http://tushnet.blogspot.com/2025/08/court-rejects-schedule-claims-against.html

Posted in Uncategorized | Tagged | Leave a comment

drug company plausibly alleged confusion about partnership but not falsity of “same drug” claims about Canadian imports

AbbVie Inc. v. Payer Matrix, LLC, No.
23 CV 2836, 2025 WL 2374490 (N.D. Ill. Aug. 15, 2025)

AbbVie sells the specialty drugs Humira, Skyrizi, and
Rinvoq. Payer Matrix is “an alternative funding provider that works with
self-funded health plans to lower their specialty drug costs.” AbbVie brought
various claims against Payer Matrix based on Payer Matrix’s alleged involvement
with AbbVie’s charitable programs, including AbbVie’s Patient Assistance
Program (PAP) and Co-Pay Assistance Program (CAP). AbbVie also brought claims
based on Payer Matrix allegedly facilitating the importation of AbbVie drugs
from Canada. The court allows some claims to proceed, including trademark
claims despite the sophistication of the consumers.

A RICO claim survived, amazingly enough.

Lanham Act false association: AbbVie’s complaint identified
a Payer Matrix presentation “showing AbbVie’s trademark-protected logo and the
trademarks of other pharmaceutical manufacturers under a title ‘We partner with
top manufacturers.’ ” OK, even I would not say “partner with” is ok absent a relationship.

On the other hand, the court also thought another statement
in a presentation plausibly suggested a business relationship, which seems
silly to me. Discussing a slide that included AbbVie’s logo under a title “Top
Manufacturers,” the presenter said pharmaceutical manufacturers were putting
specialty drugs “down two runways”:

One is the traditional plan sponsor
access system, by which you’re paying probably 1,000 times what it costs them
to make the drug, and then there’s another pathway you can follow, which is the
Manufacturer Assistance Program, and really, what these big pharma
organizations are doing is they’re allowing access on both sides, but frankly,
a lot of people don’t know how to get access to the side that’s significantly
reduced in cost, and they do it for a variety of reasons … but the bottom
line is we’re a model that’s actually helping plans tap into these programs,
which are overfunded and underutilized.

Then, back to something that is a bit more plausible, the
presenter “told his audience that by permitting Payer Matrix access to its PAP
and CAP programs, AbbVie was improving its reputation; earning a tax deduction;
and ‘expand[ing] the net of who they’re getting onto these particular drugs.’”
And then back to silly: AbbVie also alleged that other Payer Matrix “marketing
materials deceptively represent[ed] that its program leverages ‘extensive,
often unused funds made available by Pharma Manufacturers.’ ”

As a whole, “these statements could plausibly confuse a plan
sponsor into believing that AbbVie approved of Payer Matrix’s PAP and CAP
activities.” The court emphasized the bad “[w]e partner with top manufacturers”
slide, as well as an allegation that at least one plan sponsor working with
Payer Matrix “was led to believe and represented to its members that Payer
Matrix seeks ‘grant money’ from pharmaceutical companies to reduce the cost of
some specialty drugs.” But the court also highlighted the statement that AbbVie
“win[s] from a financial standpoint” by accepting patients into its “overfunded
and underutilized” PAP, reasoning that “a plan sponsor could rationally
understand such a statement to mean that AbbVie endorses Payer Matrix’s scheme
of enrolling members in the PAP.” This seems clearly fixable with a proximate
disclaimer (and eliminating the partnership language).

“Partner” was also not puffery, since it has a defined
meaning, i.e., “to join with another person or
organization in a business activity.”
Nor was client sophistication enough
to defeat the argument at the pleading stage.

As to drug importation, AbbVie alleged that the medicines
Payer Matrix imports, or helps import, from Canada are “likely to cause
consumer confusion, given the material differences between these medicines and
their domestic counterparts.” AbbVie argued that it only needed to show a
material difference in the products, but § 1125(a)(1)(A) still requires a false
or misleading representation “likely to confuse or deceive their audience about
the plaintiff’s ‘affiliation, connection, or association’ with the defendant
‘or as to the origin, sponsorship, or approval of his or her goods, services,
or commercial activities.’ ”

And “the closest AbbVie comes to meeting this mark is its
allegation that Payer Matrix advertises RxFree4Me’s Canadian-sourced medicines
as the ‘same brand medications.’” That “says nothing about whether AbbVie
sponsors or approves of the drugs’ importation and the processes and procedures
through which the importation happens.” Thus, it wasn’t plausible that AbbVie would
be held “responsible for any medicine shipping delays and any counterfeit,
adulterated, mislabeled, ineffective, or spoiled product that [patients]
receives through Payer Matrix’s program.” And, while “same brand” “inherently
suggests some affiliation or association between AbbVie and the imported
AbbVie-branded drugs, AbbVie also alleges nothing to suggest that this
intimation was, in fact, false or deceptive.” This is a really useful point
about grey market goods—if they’re imported not for resale by someone who
understands they’re importing, then there’s really nothing misleading even if
there are material differences.

False advertising: AbbVie challenged: (1) advertisements on
Payer Matrix’s website saying that patients will not experience any disruption
or change in their specialty drug access, (2) statements Payer Matrix made to
doctors during drug-conversion efforts, (3) statements made to plan sponsors,
brokers, and doctors about AbbVie’s restrictions on PAP access, (4) Payer
Matrix’s representations that the imported AbbVie medicines come from
“legitimate and valid” sources, and (5) Payer Matrix’s statements about
partnering with AbbVie.

Ads claiming no disruption or change in access: Payer
Matrix’s website read: “[M]embers are not disrupted and always receive their
medications. There is no interruption in supply, no requirements to change
brands or dosing, the only difference is the source of the medication, and of
course the reduced costs.” AbbVie alleged falsity because (1) “members do in
fact have interruption in supply, including medicine delays,” (2) “Payer Matrix
does ask the members’ [health care providers (“HCPs”)] to change their medicine
brands when Payer Matrix is unable to maneuver the members into AbbVie’s PAP,”
and (3) “the statement that ‘the only difference is the source of the
medication’ misleadingly suggests that Payer Matrix is the members’ new
insurance provider for their specialty drugs.”

Payer Matrix argued that AbbVie’s injury was not proximately
caused by these statements.  But “AbbVie’s
theory of economic harm is plausible: when the advertisement turns out to be
false, customers may very well wrongly blame AbbVie—not Payer Matrix—for
interruptions in supply or changes to their medications…. At this early stage,
AbbVie plausibly pleads under Lexmark that its reputation was harmed by
the allegedly false representations on Payer Matrix’s website.”

Statements to doctors: AbbVie alleged false and misleading
statements to doctors that the patients no longer had the ability to obtain
their AbbVie drug and that the HCPs, therefore, had no choice but to change
their prescriptions.” Allegedly, “Payer Matrix employees would typically tell
the HCPs that the patients were uninsured for specialty drugs and/or no longer
had access to AbbVie’s PAP, often disparaging and blaming AbbVie in the
process.”

But these statements weren’t made “in commercial advertising
or promotion.” Whether this violated other laws was “beside the point”: when talking
to doctors, “Payer Matrix was not trying to ‘promote’ or ‘advertise’ anything”
but to persuade doctors to switch prescriptions. “[I]f Payer Matrix were trying
to promote its services, the ‘relevant purchasing public’ would be plan
sponsors and their brokers—not doctors.”

Alleged disparagement campaign: Payer Matrix emails
allegedly stated that: (1) “AbbVie has cut off PAP access to any patients
working with third parties and patient advocacy groups,” (2) “AbbVie has shut
the door on PAP to those who are underinsured,” (3) “AbbVie has been converting
existing Humira patients to Skyrizi for financial gain,” and (4) “AbbVie is no
longer accepting PAP applications at all.” Again, these weren’t commercial
advertising or promotion, but rather statements made in the course of “providing
services it had already agreed to provide”:

While some cases suggest that
statements made to a company’s existing customer base can support a Lanham Act
claim, the statements still must “advertise” or “promote” the company’s product
or services. These statements plainly did not. If anything, as Payer Matrix
points out, the statements would have deterred customers from working with
Payer Matrix “given that AbbVie[’s] own allegations contend that the accessibility
of PAP programs is a necessary prerequisite to Payer Matrix’s business model.”

Statements about imported drugs: AbbVie alleged that Payer
Matrix falsely claimed “that the medicines obtained through its importation
program … come from ‘legitimate and valid sources,’ despite the fact that
these medicines are being illegally imported from outside the United States.” This
was ambiguous: “generic words such as ‘legitimate’ and ‘valid’ cannot
reasonably be construed as synonymous with ‘FDA-approved’ or ‘FDCA-compliant.’
” Also, Payer Matrix said that, as part of RxFree4Me’s international drug
sourcing program, “[m]embers receive their same brand medications delivered to
their door for a $0 copay.” AbbVie didn’t allege that the imported medicines
are not actually AbbVie-brand medicines. A reasonable person would not be
misled into thinking that “same brand” means “same regulatory approval
process.” Motion to dismiss as to these allegations granted.

Partnership/approval statements: Again, partnership was
objectively verifiable and “plainly goes to the nature of Payer Matrix’s
services.” (The other statements, though, seem at least ambiguous to me.)
Still, it was “plausible that a plan sponsor listening to Payer Matrix’s
presentations could be misled into thinking that AbbVie endorses (and even
aids) Payer Matrix’s methods for enrolling its members in AbbVie’s PAP and CAP
and that this plan sponsor would be persuaded to procure Payer Matrix’s
services as a result.” [What harm does this do AbbVie?]

State law claims: Illinois Consumer Fraud and Deceptive
Business Practices Act (ICFA), tortious interference, and common law fraud
claims all turned on whether Payer Matrix misrepresented members’ coverage
status. When facilitating its members’ PAP applications, Payer Matrix submitted
requests to AbbVie saying that its members were “responsible for 100% of the
cost of their drugs or that their drugs have been excluded from their plans’
formularies.” To the contrary, AbbVie alleged that the member’s employer (i.e.,
the plan sponsor) had every intention of covering the cost of the drug if the
member was ultimately denied from AbbVie’s PAP. It alleged that Payer Matrix’s
“clients’ amended [Summary Plan Descriptions] … commonly contain language
informing members that their specialty drugs will continue to be covered by the
plan if Payer Matrix is unable to obtain alternate funding” and that Payer
Matrix’s client brochures and marketing materials say the same, “confirming
that overrides are granted as a matter of course when PAP admission is denied
and that the purported specialty drug exclusion is a sham.” Thus, AbbVie
plausibly alleged that Payer Matrix misrepresented the truth when it
communicated to AbbVie that members were responsible for 100% of the cost of
their drugs.

Payer Matrix argued that AbbVie did not rely on the submissions
“given that [AbbVie] conducted independent benefits investigations,” but AbbVie
alleged otherwise. And Payer Matrix was plausibly responsible even if patients
formally certified the forms, given allegations that Payer Matrix (1) submitted
the forms knowing they falsely represented the members’ insurance status, (2)
concealed the relevant terms from patients who signed the applications, and (3)
provided PBMs and plan sponsors with the forms template.

ICFA: As a non-consumer, AbbVie needed a “consumer nexus,” that
is, it needed to show that “the alleged conduct involves trade practices
addressed to the market generally or otherwise implicates consumer protection
concerns.” Non-consumers need to show that their actions were akin to a
consumer’s actions. “Consumer protection concerns” are implicated where the
defendant’s conduct “involves sharp practices designed to mislead consumers
about a competitor” or “public health, safety or welfare issues.”

AbbVie didn’t satisfy this standard. “Even if Payer Matrix’s
allegedly deceptive conduct might ultimately hurt specialty drug patients,
AbbVie does not act in a role akin to a consumer when it accepts or denies
patients from its PAP and CAP.” While consumers could be harmed by delays in
getting their drugs, having prescriptions changed unnecessarily, and related
uncertainty, the harm to AbbVie was primarily economic: “an increase in the
operational costs associated with its patient assistance programs and a loss of
sales.” Operational and financial issues are distinct to access-to-health-care
issues, and awarding AbbVie economic damages would not “serve the interests of
consumers.” Dismissed with prejudice.

Illinois Uniform Deceptive Trade Practices Act: the prohibitions
on confusion and false advertising parallel the Lanham Act, above. AbbVie
argued that, “for IDTPA liability, deceptive statements do not have to occur in
the context of commercial advertising.” But an IDPTA claim requires
“advertising,” and the Seventh Circuit has previously applied its Lanham Act
standard unchanged, so the court didn’t agree.

Tortious interference: In Illinois, a plaintiff must prove:
“(1) his reasonable expectation of entering into a valid business relationship;
(2) the defendant’s knowledge of the plaintiff’s expectancy; (3) purposeful
interference by the defendant that prevents the plaintiff’s legitimate
expectancy from ripening into a valid business relationship; and (4) damages to
the plaintiff resulting from such interference.”

To the extent AbbVie’s tortious interference claim relied on
Payer Matrix’s facilitation of imported drugs from Canada, AbbVie’s claim failed
because there were no allegations that Payer Matrix made any false or
misleading statements about the imported drugs or that Payer Matrix falsely
said they are FDA-approved.

However, Payer Matrix’s facilitation of PAP applications and
drug-conversion efforts could plausibly be tortious interference.

Common-law fraud: AbbVie alleged that Payer Matrix fraudulently
represented to AbbVie that PAP applicants lacked commercial insurance coverage
for Skyrizi, Humira, and Rinvoq, even though the plans guaranteed coverage for
those medicines if they were denied PAP benefits. This requires: “(1) a false
statement of material fact; (2) defendant’s knowledge that the statement was
false; (3) defendant’s intent that the statement induce the plaintiff to act;
(4) plaintiff’s reliance upon the truth of the statement; and (5) plaintiff’s
damages resulting from reliance on the statement.” This was plausibly pled.

from Blogger http://tushnet.blogspot.com/2025/08/drug-company-plausibly-alleged.html

Posted in Uncategorized | Tagged , , | Leave a comment